

---

Wee Kiat is the Chief Operating Officer in CytoMed Therapeutics Pte Ltd; an A\*STAR spin-off in Singapore. Prior to this, he served as a research scientist in another biotech company and was responsible for process mapping and development for cell-based immunotherapy.

He received his Ph.D from National University of Singapore (NUS) in 2016. His research focus is on cell-based cancer immunotherapeutics using a wide variety of immune cells including Natural Killer cells, gamma delta ( $\gamma\delta$ ) T cells, dendritic cells and CAR-  $\gamma\delta$  T cells. Also experienced with using Baculovirus mediated gene delivery and human induced pluripotent stem cell (hiPSC) reprogramming and differentiation, he is now dedicated to driving CytoMed Therapeutics' platform technologies into clinical applications and therapeutics for cancer therapy.